Using noninvasive sensory stimulation to help clear toxic proteins in Alzheimer's disease
Noninvasive sensory stimulation to promote glymphatic-lymphatic clearance for the treatment of Alzheimer’s Disease
['FUNDING_R01'] · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · NIH-11074676
This study is exploring a new way to help people with Alzheimer's by using gentle sensory techniques to boost the brain's ability to clear out harmful substances, and it's currently being tested in mice to see how well it works.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (nih funded) |
| Locations | 1 site (CAMBRIDGE, UNITED STATES) |
| Trial ID | NIH-11074676 on ClinicalTrials.gov |
What this research studies
This research investigates a novel approach to treating Alzheimer's disease by using noninvasive sensory stimulation techniques to enhance the brain's natural waste clearance systems. The study focuses on a method called Gamma ENtrainment Using Sensory stimuli (GENUS), which aims to induce specific brain wave patterns that may improve the clearance of harmful amyloid and tau proteins. By testing this approach in mouse models of Alzheimer's, researchers hope to understand how it affects brain fluid movement and the removal of toxic substances. If successful, this could lead to new therapeutic strategies for patients with Alzheimer's disease.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with Alzheimer's disease or those exhibiting early signs of cognitive decline.
Not a fit: Patients with other forms of dementia or neurological disorders unrelated to Alzheimer's may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new noninvasive treatment option that helps reduce toxic protein accumulation in the brains of Alzheimer's patients.
How similar studies have performed: While the specific approach of using GENUS is novel, similar noninvasive techniques have shown promise in other studies targeting brain health and cognitive function.
Where this research is happening
CAMBRIDGE, UNITED STATES
- MASSACHUSETTS INSTITUTE OF TECHNOLOGY — CAMBRIDGE, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: TSAI, LI-HUEI — MASSACHUSETTS INSTITUTE OF TECHNOLOGY
- Study coordinator: TSAI, LI-HUEI
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Alzheimer disease dementia, Alzheimer syndrome